Member Info for stephen11

We already have an impressive list of well respected world-wide distribution partners for the MT-RNR1 ID (Hearing loss) Kit. These partners have all went through a stringent due diligence check list by GDR, as described in the Nov 2022 investor presentation.

They now have all the products and software translated to all the relevant native languages thanks to the new CEO James Cheek.

Additionally, the initial orders will support genedrive's international distribution partners in promotion and in-country evaluation activities in their respective countries, to provide more extensive access to this life-changing test.

Here's the list of distributors i had previously:

- Turkey: Ertunc Ozcan

- Greece: Artisel

- Kuwait: Al Essa

- France: Eurocare

- Saudi Arabia: ideal idea

- Austria: Connect Medizintechnik GmbH

- Spain: PRHOINSA

- UK: Inspiration Healthcare (as we already know)

Interestingly, the Netherlands are an additional international partner. Saudi Arabia is also an extremely lucrative market for private health care, especially with all the foreign workers and families in the likes of the oil and petro-chemical industries.

Stephen11

Get back in your box Starresnstoff - I’ll speak to you later 👋.

Wise words that man - longtermholder14

Good on you MisterPositive - Positive times ahead indeed!

19-Dec-23 16:30:03 7.86667 300,000 Unknown* 0.00 0.00 23.60k O

See news flow for Dec 23 and Jan 24, summarised from the presentation with comments from James Cheek:

- Revenue in the UK and abroad for MTRNR-1 hearing product (Sussex Trust already life)

* Expecting to see orders from around Europe in Dec 23 (EU Market worth £46.75M annually) and more UK Trusts

- Promotion of MTRNR-1 through Health Innovation Networks

* Talks ongoing with Scotland and Wales

- Special Commissioning for MTRNR-1

* James states "Pretty much got absolute 100% clarity that it is happening" (UK market worth £8.5M annually)

- FDA registration for MTRNR-1

* James states that contracts with a US partner for FDA are being finalised and we should hear news this year or early next, on the back of extremely positive talks with the FDA (USA market worth £34M annually)

- NICE recommendation for MTRNR-1

* NICE full validation for the MTRNR-1 is being hindered by the EVO process itself and not the product. News due Jan 24 says James Cheek

- NICE review for CYP2C19

* News due Jan 2024 says James Cheek (UK market worth £8.5M annually)

- Testing in Manchester Trust for CYP2C19 and Europe

* Testing for the adverse reaction to Clipidogrel in stroke patients to roll out in Dec 23. Also being actively marketed around Europe as a research only product (EU Market worth £93.5M annually)

- Future funding activities to support FDA

* Support of US partner and specific fundraise for FDA in Q1

GLA.

Stephen11.

And in the words of the Carpenters

“It’s only just begun”

I’ll explain all in next message.

GLA.

Stephen11.

Stampee1,

In a nutshell, certain types of medication, when administered to premature babies create an Adverse Drug Reaction (ADR), that can lead to deafness.

The Genedrive test is able to distinguish, in a time critical period of 26 minutes, if such a ADR would take place. In this instance an alternative medication would be administered. Importantly, this also lets the maternal line know of the same ADR.

Not sure of the brain damage claims you mention, though this may be for bilateral white matter loss, in conditions such as CP.

GLA.

Stephen11.

But, what a great party we have to look forward to.

Welcome to the party Figes

See news flow for Dec 23 and Jan 24, summarised from the presentation with comments from James Cheek:

- Revenue in the UK and abroad for MTRNR-1 hearing product (Sussex Trust already life)

* Expecting to see orders from around Europe in Dec 23 (EU Market worth £46.75M annually) and more UK Trusts

- Promotion of MTRNR-1 through Health Innovation Networks

* Talks ongoing with Scotland and Wales

- Special Commissioning for MTRNR-1

* James states "Pretty much got absolute 100% clarity that it is happening" (UK market worth £8.5M annually)

- FDA registration for MTRNR-1

* James states that contracts with a US partner for FDA are being finalised and we should hear news this year or early next, on the back of extremely positive talks with the FDA (USA market worth £34M annually)

- NICE recommendation for MTRNR-1

* NICE full validation for the MTRNR-1 is being hindered by the EVO process itself and not the product. News due Jan 24 says James Cheek

- NICE review for CYP2C19

* News due Jan 2024 says James Cheek (UK market worth £8.5M annually)

- Testing in Manchester Trust for CYP2C19 and Europe

* Testing for the adverse reaction to Clipidogrel in stroke patients to roll out in Dec 23. Also being actively marketed around Europe as a research only product (EU Market worth £93.5M annually)

- Future funding activities to support FDA

* Support of US partner and specific fundraise for FDA in Q1

GLA.

Stephen11.

You could be right Demolition123 - a big Pharma company could gobble up GDR for breakfast.

Let's hope if this does happen we all get a fair buyout/share price.

GLA.

Stephen11.

James Cheek stated in the investmeetcompany presentation that GDR are going to stay well clear of the infectious disease market as its way to competitive and oversaturated.

The Adverse Drug Reaction market is were GDR are positioned with two unique, point of care, world beating products that are first to market and about to gain a significant amount of commercial traction.

A great time to be invested in GDR.

GLA.

Stephen11.

Welcome to the party WASU

Good info sharing Jimi - could you cut and paste the BBC South East article so I can get a read, if your schedule permits?

That’s great - Eurocare SAS are GDRs French distribution partners - let’s hope the conference generates a few orders.

I concur - well said Garonne

Agreed harrizma - James Cheek is the real deal. We now have a proven winner and true salesman at the wheel 🛞.

Thanks Muminr and BigAl67,

As you say - great volume of trades yesterday and today.

I really hope we get a big afternoon rally like yesterday.

Best Wishes,

Stephen11.

We are also hearing a significant amount of misinformation about a placing. Might i remind everyone that Q1 doesn't start to 01/01/24 and ends on the 31/03/24 - lots can happen before then, as i shall detail later.

And, its a fallacy to say that any placing will be at a significant discount, as proven over the last 4 years. I'll post a history of the placing in the last 4 years later.

In any case, James has eluded to the placing being used for FDA submission. RF drawdown, the incoming tax credits, devote funding, Medtech funding, and commercial traction can be used to cover monthly cash burn.

See news flow for Dec 23 and Jan 24, summarised from the presentation with comments from James Cheek attached:

- Revenue in the UK and abroad for MTRNR-1 hearing product (Sussex Trust already life)

* Expecting to see orders from around Europe in Dec 23 (EU Market worth £46.75M annually) and more UK Trusts

- Promotion of MTRNR-1 through Health Innovation Networks

* Talks ongoing with Scotland and Wales

- Special Commissioning for MTRNR-1

* James states "Pretty much got absolute 100% clarity that it is happening" (UK market worth £8.5M annually)

- FDA registration for MTRNR-1

* James states that contracts with a US partner for FDA are being finalised and we should hear news this year or early next, on the back of extremely positive talks with the FDA (USA market worth £34M annually)

- NICE recommendation for MTRNR-1

* NICE full validation for the MTRNR-1 is being hindered by the EVO process itself and not the product. News due Jan 24 says James Cheek

- NICE review for CYP2C19

* News due Jan 2024 says James Cheek (UK market worth £8.5M annually)

- Testing in Manchester Trust for CYP2C19 and Europe

* Testing for the adverse reaction to Clipidogrel in stroke patients to roll out in Dec 23. Also being actively marketed around Europe as a research only product (EU Market worth £93.5M annually)

- Future funding activities to support FDA

* Support of US partner and specific fundraise for FDA in Q1

GLA.

Stephen11.